IBDEI0BY ; ; 19-NOV-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15991,2)
 ;;=^295295
 ;;^UTILITY(U,$J,358.3,15992,0)
 ;;=V16.41^^85^901^9
 ;;^UTILITY(U,$J,358.3,15992,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15992,1,4,0)
 ;;=4^V16.41
 ;;^UTILITY(U,$J,358.3,15992,1,5,0)
 ;;=5^Family h/o Cancer of Ovary
 ;;^UTILITY(U,$J,358.3,15992,2)
 ;;=^317951
 ;;^UTILITY(U,$J,358.3,15993,0)
 ;;=V16.42^^85^901^10
 ;;^UTILITY(U,$J,358.3,15993,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15993,1,4,0)
 ;;=4^V16.42
 ;;^UTILITY(U,$J,358.3,15993,1,5,0)
 ;;=5^Family h/o Cancer of Prostate
 ;;^UTILITY(U,$J,358.3,15993,2)
 ;;=^317952
 ;;^UTILITY(U,$J,358.3,15994,0)
 ;;=V16.43^^85^901^11
 ;;^UTILITY(U,$J,358.3,15994,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15994,1,4,0)
 ;;=4^V16.43
 ;;^UTILITY(U,$J,358.3,15994,1,5,0)
 ;;=5^Family h/o Cancer of Testis
 ;;^UTILITY(U,$J,358.3,15994,2)
 ;;=^317953
 ;;^UTILITY(U,$J,358.3,15995,0)
 ;;=V19.5^^85^901^13
 ;;^UTILITY(U,$J,358.3,15995,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15995,1,4,0)
 ;;=4^V19.5
 ;;^UTILITY(U,$J,358.3,15995,1,5,0)
 ;;=5^Family h/o Congenital Anomalies
 ;;^UTILITY(U,$J,358.3,15995,2)
 ;;=^295325
 ;;^UTILITY(U,$J,358.3,15996,0)
 ;;=V19.2^^85^901^14
 ;;^UTILITY(U,$J,358.3,15996,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15996,1,4,0)
 ;;=4^V19.2
 ;;^UTILITY(U,$J,358.3,15996,1,5,0)
 ;;=5^Family h/o Deafness Or Hearing Loss
 ;;^UTILITY(U,$J,358.3,15996,2)
 ;;=^295322
 ;;^UTILITY(U,$J,358.3,15997,0)
 ;;=V17.3^^85^901^16
 ;;^UTILITY(U,$J,358.3,15997,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15997,1,4,0)
 ;;=4^V17.3
 ;;^UTILITY(U,$J,358.3,15997,1,5,0)
 ;;=5^Family h/o Ischemic Heart Dis
 ;;^UTILITY(U,$J,358.3,15997,2)
 ;;=^295305
 ;;^UTILITY(U,$J,358.3,15998,0)
 ;;=V16.6^^85^901^17
 ;;^UTILITY(U,$J,358.3,15998,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15998,1,4,0)
 ;;=4^V16.6
 ;;^UTILITY(U,$J,358.3,15998,1,5,0)
 ;;=5^Family h/o Leukemia
 ;;^UTILITY(U,$J,358.3,15998,2)
 ;;=^295298
 ;;^UTILITY(U,$J,358.3,15999,0)
 ;;=V18.61^^85^901^19
 ;;^UTILITY(U,$J,358.3,15999,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15999,1,4,0)
 ;;=4^V18.61
 ;;^UTILITY(U,$J,358.3,15999,1,5,0)
 ;;=5^Family h/o Polycystic Kidney
 ;;^UTILITY(U,$J,358.3,15999,2)
 ;;=^321531
 ;;^UTILITY(U,$J,358.3,16000,0)
 ;;=V17.0^^85^901^20
 ;;^UTILITY(U,$J,358.3,16000,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16000,1,4,0)
 ;;=4^V17.0
 ;;^UTILITY(U,$J,358.3,16000,1,5,0)
 ;;=5^Family h/o Psychiatric Condition
 ;;^UTILITY(U,$J,358.3,16000,2)
 ;;=^295302
 ;;^UTILITY(U,$J,358.3,16001,0)
 ;;=V19.4^^85^901^21
 ;;^UTILITY(U,$J,358.3,16001,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16001,1,4,0)
 ;;=4^V19.4
 ;;^UTILITY(U,$J,358.3,16001,1,5,0)
 ;;=5^Family h/o Skin Condition
 ;;^UTILITY(U,$J,358.3,16001,2)
 ;;=^295324
 ;;^UTILITY(U,$J,358.3,16002,0)
 ;;=V17.1^^85^901^22
 ;;^UTILITY(U,$J,358.3,16002,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16002,1,4,0)
 ;;=4^V17.1
 ;;^UTILITY(U,$J,358.3,16002,1,5,0)
 ;;=5^Family h/o Stroke (CVA)
 ;;^UTILITY(U,$J,358.3,16002,2)
 ;;=^295303
 ;;^UTILITY(U,$J,358.3,16003,0)
 ;;=V16.8^^85^901^12
 ;;^UTILITY(U,$J,358.3,16003,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16003,1,4,0)
 ;;=4^V16.8
 ;;^UTILITY(U,$J,358.3,16003,1,5,0)
 ;;=5^Family h/o Cancer,Other Specified
 ;;^UTILITY(U,$J,358.3,16003,2)
 ;;=^295300
 ;;^UTILITY(U,$J,358.3,16004,0)
 ;;=V11.1^^85^901^24
 ;;^UTILITY(U,$J,358.3,16004,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16004,1,4,0)
 ;;=4^V11.1
 ;;^UTILITY(U,$J,358.3,16004,1,5,0)
 ;;=5^Hx of Affective Disorder
 ;;^UTILITY(U,$J,358.3,16004,2)
 ;;=^295250
 ;;^UTILITY(U,$J,358.3,16005,0)
 ;;=V15.89^^85^901^46
 ;;^UTILITY(U,$J,358.3,16005,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16005,1,4,0)
 ;;=4^V15.89
 ;;^UTILITY(U,$J,358.3,16005,1,5,0)
 ;;=5^Hx of Persian Gulf Region Exposure
 ;;^UTILITY(U,$J,358.3,16005,2)
 ;;=^295291
 ;;^UTILITY(U,$J,358.3,16006,0)
 ;;=V11.3^^85^901^25
 ;;^UTILITY(U,$J,358.3,16006,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16006,1,4,0)
 ;;=4^V11.3
 ;;^UTILITY(U,$J,358.3,16006,1,5,0)
 ;;=5^Hx of Alcoholism
 ;;^UTILITY(U,$J,358.3,16006,2)
 ;;=^295252
 ;;^UTILITY(U,$J,358.3,16007,0)
 ;;=V15.07^^85^901^26
 ;;^UTILITY(U,$J,358.3,16007,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16007,1,4,0)
 ;;=4^V15.07
 ;;^UTILITY(U,$J,358.3,16007,1,5,0)
 ;;=5^Hx of Allergy to Latex
 ;;^UTILITY(U,$J,358.3,16007,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,16008,0)
 ;;=V13.4^^85^901^27
 ;;^UTILITY(U,$J,358.3,16008,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16008,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,16008,1,5,0)
 ;;=5^Hx of Arthritis
 ;;^UTILITY(U,$J,358.3,16008,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,16009,0)
 ;;=V12.72^^85^901^31
 ;;^UTILITY(U,$J,358.3,16009,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16009,1,4,0)
 ;;=4^V12.72
 ;;^UTILITY(U,$J,358.3,16009,1,5,0)
 ;;=5^Hx of Colon Polyps
 ;;^UTILITY(U,$J,358.3,16009,2)
 ;;=^303401
 ;;^UTILITY(U,$J,358.3,16010,0)
 ;;=V12.59^^85^901^30
 ;;^UTILITY(U,$J,358.3,16010,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16010,1,4,0)
 ;;=4^V12.59
 ;;^UTILITY(U,$J,358.3,16010,1,5,0)
 ;;=5^Hx of CHF
 ;;^UTILITY(U,$J,358.3,16010,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,16011,0)
 ;;=V45.81^^85^901^29
 ;;^UTILITY(U,$J,358.3,16011,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16011,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,16011,1,5,0)
 ;;=5^Hx of CABG
 ;;^UTILITY(U,$J,358.3,16011,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,16012,0)
 ;;=V15.84^^85^901^28
 ;;^UTILITY(U,$J,358.3,16012,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16012,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,16012,1,5,0)
 ;;=5^Hx of Asbestos Exposure
 ;;^UTILITY(U,$J,358.3,16012,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,16013,0)
 ;;=V15.85^^85^901^47
 ;;^UTILITY(U,$J,358.3,16013,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16013,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,16013,1,5,0)
 ;;=5^Hx of Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,16013,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,16014,0)
 ;;=V10.72^^85^901^34
 ;;^UTILITY(U,$J,358.3,16014,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16014,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,16014,1,5,0)
 ;;=5^Hx of Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,16014,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,16015,0)
 ;;=V15.3^^85^901^35
 ;;^UTILITY(U,$J,358.3,16015,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16015,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,16015,1,5,0)
 ;;=5^Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,16015,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,16016,0)
 ;;=V10.61^^85^901^37
 ;;^UTILITY(U,$J,358.3,16016,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16016,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,16016,1,5,0)
 ;;=5^Hx of Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,16016,2)
 ;;=Hx of Lymphoid Leukemia^295232
 ;;^UTILITY(U,$J,358.3,16017,0)
 ;;=V12.03^^85^901^39
 ;;^UTILITY(U,$J,358.3,16017,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16017,1,4,0)
 ;;=4^V12.03
 ;;^UTILITY(U,$J,358.3,16017,1,5,0)
 ;;=5^Hx of Malaria
 ;;^UTILITY(U,$J,358.3,16017,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,16018,0)
 ;;=V10.82^^85^901^40
 ;;^UTILITY(U,$J,358.3,16018,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16018,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,16018,1,5,0)
 ;;=5^Hx of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,16018,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,16019,0)
 ;;=V10.62^^85^901^43
 ;;^UTILITY(U,$J,358.3,16019,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16019,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,16019,1,5,0)
 ;;=5^Hx of Myeloid Leukemia
 ;;^UTILITY(U,$J,358.3,16019,2)
 ;;=Hx of Myeloid Leukemia^295233
 ;;^UTILITY(U,$J,358.3,16020,0)
 ;;=V10.63^^85^901^41
 ;;^UTILITY(U,$J,358.3,16020,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16020,1,4,0)
 ;;=4^V10.63
 ;;^UTILITY(U,$J,358.3,16020,1,5,0)
 ;;=5^Hx of Monocytic Leukemia
 ;;^UTILITY(U,$J,358.3,16020,2)
 ;;=Hx of Monocytic Leukemia^295234
 ;;^UTILITY(U,$J,358.3,16021,0)
 ;;=V11.2^^85^901^32
 ;;^UTILITY(U,$J,358.3,16021,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16021,1,4,0)
 ;;=4^V11.2
 ;;^UTILITY(U,$J,358.3,16021,1,5,0)
 ;;=5^Hx of Dysthymia
 ;;^UTILITY(U,$J,358.3,16021,2)
 ;;=Hx of Dysthymia^295251
 ;;^UTILITY(U,$J,358.3,16022,0)
 ;;=V15.81^^85^901^60
 ;;^UTILITY(U,$J,358.3,16022,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16022,1,4,0)
 ;;=4^V15.81
 ;;^UTILITY(U,$J,358.3,16022,1,5,0)
 ;;=5^Noncompliance With Medical Treatment
 ;;^UTILITY(U,$J,358.3,16022,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,16023,0)
 ;;=V10.43^^85^901^44
 ;;^UTILITY(U,$J,358.3,16023,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16023,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,16023,1,5,0)
 ;;=5^Hx of Ovarian CA
 ;;^UTILITY(U,$J,358.3,16023,2)
 ;;=Hx of Ovarian CA^295221
 ;;^UTILITY(U,$J,358.3,16024,0)
 ;;=V12.71^^85^901^45
 ;;^UTILITY(U,$J,358.3,16024,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16024,1,4,0)
 ;;=4^V12.71
 ;;^UTILITY(U,$J,358.3,16024,1,5,0)
 ;;=5^Hx of Peptic Ulcer Disease
 ;;^UTILITY(U,$J,358.3,16024,2)
 ;;=^303400
 ;;^UTILITY(U,$J,358.3,16025,0)
 ;;=V10.46^^85^901^48
 ;;^UTILITY(U,$J,358.3,16025,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16025,1,4,0)
 ;;=4^V10.46
 ;;^UTILITY(U,$J,358.3,16025,1,5,0)
 ;;=5^Hx of Prostate Cancer
 ;;^UTILITY(U,$J,358.3,16025,2)
 ;;=Hx of Prostate Cancer^295224
 ;;^UTILITY(U,$J,358.3,16026,0)
 ;;=V11.0^^85^901^50
 ;;^UTILITY(U,$J,358.3,16026,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16026,1,4,0)
 ;;=4^V11.0
 ;;^UTILITY(U,$J,358.3,16026,1,5,0)
 ;;=5^Hx of Schizophrenia
 ;;^UTILITY(U,$J,358.3,16026,2)
 ;;=Hx of Schizophrenia^295249
 ;;^UTILITY(U,$J,358.3,16027,0)
 ;;=V10.83^^85^901^51
 ;;^UTILITY(U,$J,358.3,16027,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16027,1,4,0)
 ;;=4^V10.83
 ;;^UTILITY(U,$J,358.3,16027,1,5,0)
 ;;=5^Hx of Skin Cancer (Non-Melanoma)
 ;;^UTILITY(U,$J,358.3,16027,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,16028,0)
 ;;=V15.1^^85^901^53
